Markets

Aerie Pharmaceuticals, Inc. (AERI) in Focus: Stock Rises 5.71% - Tale of the Tape

Aerie Pharmaceuticals, Inc. ( AERI ) was a big mover last session, as the company saw its shares rise nearly 6% on the day. This rally higher can be attributable to solid volume with far more shares changing hands than in a normal session. This stock, trading in a volatile price range of $13.764 to $16.57 in the past one-month time frame, showed a pick-up yesterday at $16.49.

The company has seen 1 positive revision in the past one month, while its Zacks Consensus Estimate of a loss narrowed over the same timeframe, suggesting that more solid trading could be ahead for the company. So make sure to keep an eye on this stock going forward to see if this recent move higher can last.

Aerie Pharmaceuticals currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.

Other attractive players in the healthcare industry include Illumina Inc. ( ILMN ) and Gilead Sciences Inc. ( GILD ), carrying a Zacks Rank #1 (Strong Buy) and Ariad Pharmaceuticals Inc. ( ARIA ) with a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AERIE PHARMACT (AERI): Get Free Report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

ILLUMINA INC (ILMN): Free Stock Analysis Report

ARIAD PHARMA (ARIA): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

AERI GILD ILMN

Other Topics

Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More